Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 2/20 | 0.38 |
| ▸ | INSR | P06213 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201526 | 0.90 | BRD4 (0.45) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2199344 | 0.90 | BRD4 (0.45) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL12509787 | 0.89 | KMT2A (0.50) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2199427 | 0.88 | MAPT (0.55) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2195870 | 0.88 | KDM4E (0.50) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2199667 | 0.87 | BRD4 (0.45) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2198470 | 0.87 | BRD4 (0.47) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| Hydrochloric Acid SCHEMBL2198617 | 0.87 | KDM4E (0.49) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2200493 | 0.86 | BRD4 (0.46) | BRD4IKBKBMEN1KMT2ANR1I2 | |
| SCHEMBL2200749 | 0.86 | BRD4 (0.52) | BRD4IKBKBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | claimed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | claimed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-2116530-B1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977371-B2 | Pyrrole derivative having ureido group and aminocarbonyl group as substituents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2116530-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | Santen Pharmaceutical Co., Ltd (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099675-A1 | NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS | UACA, IL6, IL6ST | BRD4 497/4885IKBKB 74/4885MEN1 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.